Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
Alexandria T M Lee, Misako Nagasaka · 2024
Read Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC by Alexandria T M Lee, Misako Nagasaka (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11664093.txt.
Description
A lung cancer drug that once looked like a breakthrough is stalling at the same wall as its rival, and Alexandria Lee and Misako Nagasaka examine why in a 2024 commentary. Adagrasib blocks KRAS G12C, a common driver mutation in non-small cell lung cancer. It won accelerated approval in late 2022 after early trials showed tumors held for a median of six and a half months.
The large KRYSTAL-12 trial then reported five and a half months before progression, better than the old chemotherapy's figure near four. Yet that is short of the six-month line the field quietly treats as a benchmark. The first drug of the class, sotorasib, missed the same line in its big trial. The authors question the drug's value as standard second-line care and press for stronger or combined therapies.
Catalog record
| CREATOR | Alexandria T M Lee, Misako Nagasaka |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |